D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

October 31, 2017

Conditions
SchizophreniaSchizoaffective DisorderDelusional Disorder
Interventions
DRUG

D-Cycloserine

Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.

OTHER

Placebo

Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.

BEHAVIORAL

Cognitive Behavioral Therapy

Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.

Trial Locations (2)

10016

New York Langone Medical Center/Bellevue Hospital, New York

21204

Sheppard Pratt, Baltimore

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

NYU Langone Health

OTHER

NCT01981759 - D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions | Biotech Hunter | Biotech Hunter